Moderna Announces Preliminary Booster Data, Updates Strategy to Address COVID-19 Variant Omicron
The currently authorized 50 µg booster of mRNA-1273 increased antibody levels against Omicron variant approximately 37-fold compared to pre-boost levels and a 100 µg dose of mRNA-1273 increased antibody levels approximately 83-fold compared to pre-boost levels.
Moderna on Monday announced preliminary neutralizing antibody data against the Omicron variant following the Company’s booster candidates at 50 µg and 100 µg dose levels. As per Moderna, the currently authorized 50 µg booster of mRNA-1273 increased antibody levels against Omicron variant approximately 37-fold compared to pre-boost levels and a 100 µg dose of mRNA-1273 increased antibody levels approximately 83-fold compared to pre-boost levels.
Check Tweet:
(SocialLY brings you all the latest breaking news, fact checks and information from social media world, including Twitter (X), Instagram and Youtube. The above post contains publicly available embedded media, directly from the user's social media account and the views appearing in the social media post do not reflect the opinions of LatestLY.)